Halozyme Therapeutics Inc (HALO):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Halozyme Therapeutics Inc (HALO) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7273
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes to provide innovative products for cancer, dermatology, diabetes and drug delivery markets. The company’s marketed product, Hylenex is an agent for drug and fluid infusion. Its pipeline products include analog insulin PH20, for the treatment of diabetes; PEGPH20, for the treatment of pancreatic cancer; and HTI-501, for the treatment of scarring, among others. Its products are based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes affecting the extracellular matrix. Its Enhanze technology is a novel drug delivery platform proposed to enhance the absorption and dispersion of biologics. The company has partnerships with Pfizer, Roche, Baxter and Intrexon for the development and commercialization of drugs. Halozyme is headquartered in San Diego, California, the US.

Halozyme Therapeutics Inc (HALO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Halozyme Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Halozyme Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Equipment, Deal Details 10
Partnerships 10
Halozyme Therapeutics Enters into Co-Development Agreement with Ventana Medical Systems for Cancer Treatment 10
Equity Offering 11
Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 11
Halozyme Therapeutics Inc – Key Competitors 13
Halozyme Therapeutics Inc – Key Employees 14
Halozyme Therapeutics Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 16
Financial Announcements 16
Aug 08, 2018: Halozyme reports second quarter 2018 results 16
May 10, 2018: Halozyme Reports First Quarter 2018 Results 18
Feb 20, 2018: Halozyme Reports Fourth Quarter And Full-Year 2017 Results 19
Nov 07, 2017: Halozyme Reports Third Quarter 2017 Results 20
Aug 08, 2017: Halozyme Reports Second Quarter 2017 Results 22
May 09, 2017: Halozyme Reports First Quarter 2017 Financial Results 23
Feb 28, 2017: Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results 25
Corporate Communications 27
Sep 05, 2018: Halozyme appoints Benjamin Hickey as Chief Commercial Officer 27
Other Significant Developments 28
Jan 09, 2018: Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Halozyme Therapeutics Inc, Medical Equipment, Key Facts, 2017 2
Halozyme Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Halozyme Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Deals By Market, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Halozyme Therapeutics Enters into Co-Development Agreement with Ventana Medical Systems for Cancer Treatment 10
Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 11
Halozyme Therapeutics Inc, Key Competitors 13
Halozyme Therapeutics Inc, Key Employees 14
Halozyme Therapeutics Inc, Subsidiaries 15

List of Figures
Halozyme Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Halozyme Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Halozyme Therapeutics Inc (HALO):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sinopharm Group Co Ltd (1099):製薬・医療:M&Aディール及び事業提携情報
    Summary Sinopharm Group Co Ltd (Sinopharm), a subsidiary of China National Pharmaceutical Group Corp is a distributor of pharmaceutical and healthcare products. The group provides distribution, logistics and other value-added services to foreign and domestic manufacturers and suppliers of pharmaceut …
  • Vinci SA:企業のM&A・事業提携・投資動向
    Vinci SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vinci SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Chaman Lal Setia Exports Ltd:企業の戦略・SWOT・財務情報
    Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report Summary Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Pioneer Natural Resources Co Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Pioneer Natural Resources Co Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Pioneer Natural Resources Co (Pioneer) is an independent oil and natural gas exploration and production company. Its principally operates in Eagle Ford Shale, Permian Basin, Raton Basin, …
  • Deutsche Borse Ag:企業の戦略・SWOT・財務分析
    Deutsche Borse Ag - Strategy, SWOT and Corporate Finance Report Summary Deutsche Borse Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Verizon Connect:企業の戦略的SWOT分析
    Verizon Connect - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • International Business Machines Corporation:企業の戦略・SWOT・財務情報
    International Business Machines Corporation - Strategy, SWOT and Corporate Finance Report Summary International Business Machines Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Cellnovo Ltd-医療機器分野:企業M&A・提携分析
    Summary Cellnovo Ltd (Cellnovo), formerly Starbridge Systems Ltd is a provider of conventional diabetes care technology solutions. The company offers mobile diabetes management system, including an insulin patch pump, activity monitor, cellular-enabled wireless touchscreen handset with integrated bl …
  • Postal Savings Bank of China Co., Ltd. (1658):企業の財務・戦略的SWOT分析
    Postal Savings Bank of China Co., Ltd. (1658) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Bioasis Technologies Inc (BTI):医療機器:M&Aディール及び事業提携情報
    Summary Bioasis Technologies Inc (BTI) is a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents across t …
  • Bare Escentuals Inc.:企業の戦略的SWOT分析
    Bare Escentuals Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • CS Communication & Systemes SA:企業の戦略・SWOT・財務分析
    CS Communication & Systemes SA - Strategy, SWOT and Corporate Finance Report Summary CS Communication & Systemes SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • NovaBay Pharmaceuticals Inc (NBY)-医療機器分野:企業M&A・提携分析
    Summary NovaBay Pharmaceuticals Inc (NovaBay), formerly NovaCal Pharmaceuticals Inc is a biopharmaceutical company that develops eyecare products. The company’s products include daily lid and lash hygiene spray solution, skin and wound cleanser, and cosetic procedures. Its daily lid and lash hygiene …
  • Odakyu Electric Railway Co., Ltd. (9007):企業の財務・戦略的SWOT分析
    Odakyu Electric Railway Co., Ltd. (9007) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • BioClin Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity of FGFR3 (fibroblast growth factor receptor 3) and does not interact …
  • Ethypharm SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Ethypharm SA (Ethypharm), a subsidiary of Astorg Partners is a pharmaceutical company that develops and manufactures drugs for the treatment of pain, gastrointestinal, cancer, cardiovascular and central nervous system diseases. The company provides products such as ibuprofen, paracetamol, pr …
  • National Gas & Industrial Co (2080):企業の財務・戦略的SWOT分析
    National Gas & Industrial Co (2080) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Unisem (M) Berhad (UNISEM):企業の財務・戦略的SWOT分析
    Unisem (M) Berhad (UNISEM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • PepVax Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PepVax Inc (PepVax) is a biotechnology company that develops novel therapeutics for the treatment of cancer. The company provides pipeline product candidate portfolio such as HCA587, which is being developing to treat hepatocellular carcinoma and TFDP3, a drug candidate which is being used f …
  • Sarawak Energy Berhad:企業の戦略的SWOT分析
    Sarawak Energy Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆